Integra Lifesciences Holdings (STU:IL3) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IL3 Integra Lifesciences Holdings Corp STU:IL3
73 GF Score
Price €16.80
GF Value €20.56
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is Integra Lifesciences Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Integra Lifesciences Holdings is: High Risk: High uncertainty with risk-return tradeoff.

Integra Lifesciences Holdings  (STU:IL3) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Integra Lifesciences Holdings Risk Assessment Related Terms

STU:IL3 vs ATEC, AHCO, INSP: Risk Assessment Comparison

For the Medical Devices subindustry, Integra Lifesciences Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integra Lifesciences Holdings Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's Risk Assessment falls into.


STU:IL3
73GF Score
Integra Lifesciences Holdings Corp STU:IL3
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Integra Lifesciences Holdings (STU:IL3) Overvalued in 2026?

Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued. The current stock price of €16.80 is trading 18.3% below its estimated GF Value™ of €20.56. GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.

Key valuation signals for STU:IL3:

  • Risk Assessment:
  • GF Value™: €20.56 vs. price of €16.80 (18.3% below fair value)
  • GF Score™: 73/100 with 11 warning signs

No single metric tells the full story. See the STU:IL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integra Lifesciences Holdings Business Description

Other Exchanges IART:USA
Address 1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
73GF Score

Get the complete analysis for STU:IL3

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.80
Price
€20.56
GF Value